Assessing Infrastructure And Contextual Factors In Relation To Cardiometabolic Outcomes In Remote Indigenous Communities: Evidence For Policy Change
Funder
National Health and Medical Research Council
Funding Amount
$1,113,005.00
Summary
Cardiometabolic diseases account for the major burden of morbidity and mortality for Indigenous populations. This study with 75 remote Indigenous communities will be the first to evaluate features of their social, built and physical environments in relation to cardiometabolic risks and diseases. Policy-relevant results will identify features of environments to be targeted to reduce chronic diseases for Indigenous peoples in remote communities.
The GOOD NIGHT Project: A Sleep Intervention To Prevent Depression And Improve Cardiac Health In Adolescence
Funder
National Health and Medical Research Council
Funding Amount
$902,741.00
Summary
There is a pressing need for effective approaches to preventing depression during adolescence. The primary aim of the project is to assess whether a brief sleep intervention can prevent depression in vulnerable adolescents. Given that sleep interventions also encourage daytime activity, which when combined with improved sleep has potential benefits for cardiovascular health, the secondary aim is to test whether the sleep intervention improves early indicators of cardiovascular risk.
Improving The Neonatal Transition In Infants With A Congenital Diaphragmatic Hernia
Funder
National Health and Medical Research Council
Funding Amount
$551,644.00
Summary
Congenital diaphragmatic hernia is a common congenital abnormality and occurs when the diaphragm fails to separate the abdominal and thoracic compartments before birth. This prevents the lung from growing properly and so at birth, the lung is unable to take over the role of gas exchange without considerable assistance. As a result, these infants are at high risk of death or significant disability and this application is focused on improving care and reducing morbidity in these infants.
Sex Hormones And Heart Disease In Older Women Study (The SHOW Study)
Funder
National Health and Medical Research Council
Funding Amount
$594,672.00
Summary
Cardiovascular disease (CVD, heart disease and stroke) is the leading cause of death in women aged 65 and over. Counter-intuitively, androgens may be as, or even more important, than estrogens in determining CVD risk and all-cause mortality in women, but this is yet to be verified. We will document blood levels of androgens in women aged 70+ and determine whether androgens are associated with CVD and death in this large cohort of elderly well women.
AusDiab 3: Emerging Risk Factors For And Long-term Incidence Of Cardio-metabolic Diseases
Funder
National Health and Medical Research Council
Funding Amount
$2,616,397.00
Summary
This study will track 11,000 Australian adults over 12 years to determine how many develop diabetes, obesity, kidney and heart disease. The study will develop ways to best predict those who are going to develop these conditions before they have arisen, and will explore a range of novel risk factors to better understand these conditions.
M-PreM Study: Reproductive Factors, From Menarche To Pre-menopause, And The Risk Of Cardiometabolic And Respiratory Conditions Before Menopause
Funder
National Health and Medical Research Council
Funding Amount
$1,366,831.00
Summary
This study will investigate links between reproductive factors and body size of premenopausal women with their risk of major chronic conditions, such as cardiovascular disease, diabetes, and asthma. It builds on two decades of survey data from Australia’s flagship study of women’s health with a new biomedical assessment. Findings will guide the use of indicators of women’s reproductive health as a trigger for early and targeted approaches for chronic disease prevention.
Reducing Morbidities In Preterm Growth Restricted Neonates.
Funder
National Health and Medical Research Council
Funding Amount
$687,214.00
Summary
Intrauterine growth restriction (IUGR) is a serious complication of pregnancy and occurs when fetal growth is abnormal, resulting in a fetus that is smaller than it should be for its given gestational age. IUGR babies are at much greater risk of many short and long-term adverse outcomes. This study investigates the role that adverse cardiovascular development plays in the progression of lung, heart and brain disease in preterm IUGR newborns.
The Management To Optimise Diabetes And MEtabolic Syndrome Risk Reduction Via Nurse-led Intervention (MODERN) Study
Funder
National Health and Medical Research Council
Funding Amount
$1,445,861.00
Summary
There is increasing recognition of society’s responsibility to provide effective and sustainable health care to the entire population and not just selected parts. This practical study will test the impact of a nurse-led, multidisciplinary prevention program to reduce the risk of future cardiovascular events in middle-aged individuals at a high risk of developing cardiovascular disease (CVD) living in regional Australia.
Improving Delivery Of Secondary Prophylaxis For Rheumatic Heart Disease: A Stepped-wedge, Community-randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,913,074.00
Summary
Rheumatic heart disease (RHD) is a major health problem in Indigenous communities. Continued progress in controlling RHD requires an understanding of how to improve delivery of regular injections of penicillin - secondary prophylaxis (SP). We will evaluate a systems-based approach to improving delivery of SP, using a stepped-wedge trial in 12 communities in NT and Qld. If successful, this model will provide a practical and transferable model.
The balance between cellular survival and death must be tightly regulated. Cells respond to viral infection by self-destructing, thus limiting viral spread to other cells. Viruses have evolved ways to subvert this defensive cell suicide. This project will define and characterise viral factors that maintain host cell survival during infection. These may be targets for the development of new anti-viral therapies and vaccines.